PDL BioPharma (PDLI) Posts Q1 EPS of $0.04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq futures drop over 1% as AI worries resurface, oil climbs
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts PDLI Hot Sheet
Price: $2.47 --0%
Financial Fact:
General and administrative expenses: 10.4M
Today's EPS Names:
SICP, MNSB, CFFI, More
Financial Fact:
General and administrative expenses: 10.4M
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
PDL BioPharma (NASDAQ: PDLI) reported Q1 GAAP EPS of $0.04, which may not compare to the analyst estimate of $0.05. Revenue for the quarter came in at $45.4 million versus the consensus estimate of $50.23 million.
For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Visteon (VC) Misses Q3 EPS by 214c
- Ardagh Metal Packaging S.A. (AMBP) Reports In-Line Q3 EPS
- Ryder System (R) Tops Q3 EPS by 18c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
